Clinical trials: TACE
Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization)
Effectiveness of Enhanced Web-Based Health Education on Self-Care Practices and Quality of Life Among Patients With Hepatocellular Carcinoma Undergoing TACE
This randomized controlled trial aims to evaluate the effectiveness of enhanced web-based health education on self-care practices and quality of life among patients with hepatocellular carcinoma.
- Conditions
- Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization), Web-based Intervention, Quality of Life
- Trial name
- NCT07825519
- Testing
- Enhanced Web-Based Health Education, Routine Health Education
- Where
- Vietnam
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Hepatocellular Carcinoma
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Hepatocellular carcinoma (HCC) patients with Vp4 [main trunk] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits.
- Trial name
- NCT06669377
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Zhongda Hospital
Huge Hepatocellular Carcinoma (HCC) (>10cm)
The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study
This retrospective cohort study collected data of patients with huge hepatocellular carcinoma (HCC) treated between June 1, 2018, and December 31, 2023, through the hospital information system.
- Trial name
- NCT07639294
- Testing
- hepatectomy without immune checkpoint inhibitors-based adjuvant therapy, hepatectomy with immune checkpoint inhibitors-based adjuvant therapy, neoadjuvant conversion therapy followed by surgery
- Where
- China
- Volunteers
- 715 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
- Trial name
- EMERALD-3 (NCT05301842)
- Testing
- Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE)
- Where
- 171 sites in United States, Belgium and 20 more
- Volunteers
- 760 people
- Sponsor
- AstraZeneca
Carcinoma, Hepatocellular
Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas
The purpose of the study is to evaluate the effects of Transcatheter Arterial Chemoembolization (TACE) with KMG microsphere in treating advance-stage Hepatocellular Carinoma(HCC).
- Trial name
- TACE-KMG (NCT01393093)
- Testing
- Therapeutic Chemoembolization
- Where
- China
- Volunteers
- 2,840 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Primary Hepatocellular Carcinoma
Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media
Primary Hepatocellular Carcinoma (PHC) is one of the most common malignant tumors in the world. In men is the fifth most frequently diagnosed cancer worldwide but the second most frequent cause of cancer death.
- Trial name
- NCT01563484
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Li Chen
GIST, Malignant, Liver Metastases
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
The goal of this observational study is to evaluate the overall survival benefits of local treatment combined with imatinib(IM) and IM alone in patients suffering from GIST liver metastases.
- Trial name
- NCT06038552
- Testing
- imatinib (IM), hepatic resection (HR), radiofrequency ablation (RFA)
- Where
- China
- Volunteers
- 238 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Hepatocellular Carcinoma Registry for Turkey (3K Trial)
This registry study is national, multi-center, prospective study without any interventions to the treatment strategies and/or decisions of the investigators.
- Trial name
- NCT01473121
- Testing
- No Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 600 people
- Sponsor
- Bayer
Unresectable Hepatocellular Carcinoma
Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib
This study is a single arm, single center, open label clinical trial. Recruit 34 subjects who meet the inclusion criteria and receive hepatic artery chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) combined with…
- Trial name
- NCT07230314
- Testing
- Donafina, PD-1/PD-L1 inhibitor
- Volunteers
- 34 people
- Sponsor
- Jinling Hospital, China
Hepatocellular Carcinoma
The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead
This study involves the combined use of the FDA approved device, LC Bead and the FDA approved drug, Doxorubicin for the treatment of primary hepatocellular carcinoma (HCC).
- Trial name
- NCT01259024
- Testing
- transarterial chemoembolization using a drug-eluting bead
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).
Selective Internal Radiation Therapy is superior to Transarterial Chemoembolisation for the treatment of intermediate stage hepatocellular carcinoma.
- Trial name
- NCT01798160
- Testing
- DEB TACE, SIRT
- Volunteers
- 24 people
- Sponsor
- Johannes Gutenberg University Mainz
HCC
Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients
Icaritin is a drug that has been approved by the National Medical Products Administration (NMPA) based on a multicenter, randomized, double-blind, parallel-controlled Phase III clinical trial - SNG1705 ICR-1.
- Trial name
- NCT06285149
- Testing
- Icaritin
- Volunteers
- 80 people
- Sponsor
- Henan Cancer Hospital
HepatoCellular Carcinoma
HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large hepatocellular carcinoma staged BCLC…
- Trial name
- NCT02973685
- Testing
- Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, Folfox Protocol
- Where
- 3 sites in China
- Volunteers
- 315 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. For patients with intermediate HCC (BCLC stage B), transarterial chemoembolization (TACE) has been recommended as the standard therapy in many clinical…
- Trial name
- NCT02616926
- Testing
- Hepatic resection, TACE, RFA
- Where
- 3 sites in China
- Volunteers
- 538 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Carcinoma, Hepatocellular
SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE
This is a pilot study where patients with Hepatocellular Carcinoma (HCC) that have failed Transarterial Chemoembolization (TACE) will be treated with Stereotactic Body Radiation Therapy (SBRT).
- Trial name
- NCT02221778
- Testing
- SBRT
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- University of Sao Paulo
Hepatocellular Carcinoma
Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
The goal of this prospective, interventional clinical trial is to evaluation of fruquintinib in combination with sintulimab and TACE for inoperable primary hepatocellular carcinoma for progression-free survival (PFS).
- Trial name
- NCT05971199
- Testing
- Fruquintinib, Sintilimab, Transcatheter arterial chemoembolization（TACE）
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhejiang Cancer Hospital
HCC
Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC
The goal of this Interventional Study is to compare the efficacy profile and safety of three treatments in patients with HCC nodule. Patients will be randomly divided in three arms: 1. Occlusafe assisted MWA+ DEB-TACE 2.
- Trial name
- SEASON-HCC (NCT05592171)
- Testing
- Microwave ablation + Occlusafe + DEB-TACE, Microwave ablation + Occlusafe, Microwave ablation + DEB-TACE
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Pisa
Hepatocellular Carcinoma
Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until disease progression or…
- Trial name
- NCT04483284
- Testing
- TACE combined with Camrelizumab, TACE plus Camrelizumab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Zhongshan Hospital
Radiomics, Hepatocellular Carcinoma (HCC)
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
The goal of this observational study is to explore the role of prediction of microvascular invasion by radiomics based on pre-treatment magnetic resonance imaging for guiding treatment of Barcelona Clinic Liver Cancer stage B…
- Conditions
- Radiomics, Hepatocellular Carcinoma (HCC), Transcatheter Arterial Chemoembolization (TACE), Microvascular Invasion (MVI)
- Trial name
- NCT05889949
- Testing
- Sorafenib, Lenvatinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Advanced Gastric Cancer
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
This study is a phase II, prospective, single-center, single-arm trial to evaluate the efficacy and safety of the combination of neoadjuvant transcatheter arterial chemoembolization (TACE) and PD-1 antibody Tislelizumab in the…
- Trial name
- NCT04799548
- Testing
- Transcatheter Arterial Chemoembolization, Tislelizumab
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Shanghai Zhongshan Hospital